SCHEMBL3223520

SCHEMBL3223520

CS(=O)(=O)c1ccc2c(c1)C=C(C(N)=O)[N]2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
LRRK2 Q5S007 2/20 0.36
MAP4K4 O95819 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 1/20 0.35
G6PD P11413 1/20 0.35
IDE P14735 1/20 0.35
MAPT P10636 1/20 0.35
AURKA O14965 1/20 0.34
ROCK2 O75116 1/20 0.34
CHEK2 O96017 1/20 0.34
CDK1 P06493 1/20 0.34
PIM1 P11309 1/20 0.34
FGFR3 P22607 1/20 0.34
CDK2 P24941 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
MAPK9 P45984 1/20 0.34
CSNK1D P48730 1/20 0.34
GSK3A P49840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222450 0.88 LMNA (0.36) LMNALRRK2MAP4K4ALDH1A1CYP1A2
SCHEMBL3227306 0.69 LMNA (0.39) LMNALRRK2MAP4K4G6PDIDE
SCHEMBL3223527 0.67 MAP4K4 (0.39) LMNALRRK2MAP4K4G6PDIDE
SCHEMBL4959356 0.64 MAPK1 (0.55) LMNAG6PDIDEENPP2IKBKB
SCHEMBL22148182 0.64 G6PD (0.49) LMNALRRK2MAP4K4G6PDIDE
SCHEMBL2911234 0.64 SMN1; SMN2 (0.49) LMNAG6PDIDEPDE4BENPP2
SCHEMBL13735621 0.64 G6PD (0.37) LMNAG6PDIDEENPP2AKR1C3
SCHEMBL28166017 0.64 LMNA (0.46) LMNAG6PDIDEENPP2IKBKB
SCHEMBL3222455 0.64 MAP4K4 (0.39) LMNALRRK2MAP4K4G6PDIDE
SCHEMBL1381443 0.63 CA2 (0.65) MAP4K4ENPP2AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP claimed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US claimed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US claimed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP claimed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO claimed
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 LMNA 3470/4885LRRK2 767/4885MAP4K4 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.